RxDoctor Payments Data

Aurora Bell, DO

Family Medicine · Lancaster, MONPI 1598116196

Payments from drug & device makers

$755in general payments, 2019–2025

Across 47 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$94
  • Dexcom, Inc.$90
  • Amgen$82
  • AbbVie$73
  • Otsuka America Pharmaceutical, Inc.$49
  • GSK$48
  • plus $318 from 15 others

What the payments were for

  • Food & beverage$755100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$755 in reported general payments places this provider in the 60th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$105,216
Medicare patients
210
Services billed
2,058

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HetliozTasimelteon14$330,830
Tasimelteon13$205,435
EliquisApixaban166$57,986
JardianceEmpagliflozin103$45,976
RexultiBrexpiprazole50$33,043
OzempicSemaglutide33$32,217
XareltoRivaroxaban90$24,712
TrulicityDulaglutide21$20,467
XcopriCenobamate15$18,822
VraylarCariprazine Hcl24$16,818
MounjaroTirzepatide16$16,225
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$15,991
RybelsusSemaglutide13$12,574
FarxigaDapagliflozin Propanediol29$11,812
LinzessLinaclotide40$11,637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$35$61,376177 claims
Novo NordiskOzempic, Rybelsus, Fiasp$14$49,06260 claims
Otsuka America Pharmaceutical, Inc.Rexulti$49$33,04350 claims
AbbVieVraylar, Linzess$73$28,45564 claims
AstraZenecaBreztri Aerosphere, Farxiga$27$27,80350 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$48$20,57944 claims
SK Life Science, Inc.Xcopri$13$18,82215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Lancaster

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →